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ABSTRACT
There has been an increase in demand for caregiver dosage forms over the past two decades. In the oral cavity, mouth dissolving film dissolves swiftly. 
Oral films that dissolve in your mouth function best when combined with medications that act quickly, such as Xanthine category drugs (Salbutamol 
Sulphate) and Xanthene Derivative Theophylline. According to the World Health Organization (WHO), asthma affects one in six adults and a quarter 
of all children, according to the WHO. A child’s admission to the hospital is often due to asthma, which is one of the most prevalent reasons for 
admission. During an asthma attack, quick-relief or rescue drugs are used to relax and open the airways, as well as ease symptoms. If prescribed, these 
medications can also be administered prior to exercise. To treat asthma, a combination of Salbutamol Sulfate and Theophylline is available in tablet 
form under the brand name “Theo-Asthalin.” Oral films seem to be the most efficacious formulation. As a consequence, children with asthma should 
receive support from drugs given in the form of mouth-dissolving films, since they provide better patient compliance and an appropriate treatment 
method.
Keywords: Mouth dissolving oral film, Theo-asthalin, Bronchodilators, Xanthine, Asthma.
INTRODUCTION [1‑3]
About 60% of all formulations are in solid dosage form (i.e. pills). Tablets 
are the most popular dose type since they are easy to transport and 
administer. Many types of medications, such as peptides and proteins, 
cannot be taken orally because of hepatic decomposition and enzymatic 
breakdown in the gastrointestinal tract. Chewing gums are one of the 
suggested ways for systemic drug delivery, according to recent research. 
The buccal region of the oral mucosa is one of the hypothesised 
medication delivery channels. In addition, the gastrointestinal tract’s 
enzyme flora is optimised for drug absorption by preventing hepatic 
first-pass metabolism. As early as the 1970s, a fast-dissolving drug 
delivery device (Fig. 1) when it comes to administering medications, 
the oral mucosa is a significant channel. One of the most common 
methods of developing bioadherent mucosal dosage forms is using a 
polymer matrix. The buccal cavity is lined by a stratified squamous 
epithelium, which separates the lamina propria from the sub mucosa. 
However, buccal mucosa penetrability is 4–4000 times larger than 
intestinal mucosa. Chewing is an excellent way to absorb molecules 
that do not penetrate the skin well. Because of an uppermost layer of 
membrane-covering granules that produce intercellular objects, the 
oral mucosa is porous (200 m). A 2–3-year shelf life can be expected 
for these oral film strips, depending on the active medicinal ingredient. 
In the past, patients who had difficulties swallowing tablets were 
given chewable tablets. Chewing also compromises the taste-masking 
qualities of the coating. Pre-dissolved in a glass of water, the soluble 
pills were administered to the patients, who then drank the solution. 
Taste masking, on the other hand, is more common than ever before. 
Taste masking, on the other hand, was more prominent than ever 
before. In addition, it was difficult to meet the requirement that all 
tablet components be water soluble [3].
DESCRIPTION OF THE ORAL MUCOSA (FIG. 3)
Structure [4,5]
The uppermost layer of the oral mucosa is made up of a stratified 
squamous epithelium. The sub mucosa is the next inner membrane. 
Squamous stratified epithelium, which can be found all over the body, 
is comparable to the epithelium here. The epithelial cells expand in size 
and flatten as they travel from the basal layer to the superficial layer. Oral 
epithelial formation has been documented in 5–6 days. If you have a cavity, 
the oral mucosa will be thicker than normal. This mucosa is 500–800 
microns thick, and the epithelium’s makeup varies depending on where 
in the mouth you are. Triglycerides in the keratinized epithelium serve 
as a barrier. However, the non-keratinized epithelium lacks triglycerides, 
making it relatively impermeable. Small quantities of cholesterol, 
ceramides, and other polar lipids are also present. Evidence suggests that 
epithelial water permeability exceeds that of keratinized epithelium [5].
Permeable [6]
The oral mucosa is an epithelium with a small amount of leakage. The 
oral mucosa is 44,000 times more permeable than the skin. Various 
oral mucosal architecture and functions contribute to differences in 
permeability. Clearly, the sublingual mucosa is more permeable than the 
cheek side or palate. Permeability barriers are believed to be the result of 
intercellular material developing in the oral mucosa and being coated with 
membranes membrane-coating granules (MCGs). During the separation 
process, MCG is generated and adheres to the cell’s surface at the apical 
end of the cell’s surface. Into the intercellular gap of the third epithelial 
layer, the protoplast sheath and contents are poured. Obstacles can be seen 
in plain sight on the surface layer. Horseradish peroxidises and lanthanum 
nitrate are used in penetration tests. When applied to the sub mucosal 
surface, permeation of cells is therefore hindered by cell layers with flat 
surfaces, while cells with bigger diameters have a reasonable ability to 
permeate. For prevention purposes, it turned out that keratinisation 
wasn’t a good idea. In contrast, the non-keratinized epithelial MCG has a 
non-lamellar stack of lipids. Ceramides, sphingomyelin, and glucochamber 
ceramide make up the MCG lipids of the keratinized epithelium. However, 
mucosal penetration is still constrained by the exterior epithelium, in 
addition to the basement membrane. The basal layer’s composition is not 
dense enough to remove big molecules [6].
Environment [7]
Mucus, a mixture of proteins and carbohydrates, surrounds oral 
epithelial cells in the mouth. Cells can move freely because mucus acts 
as a lubricant and as a binding agent. Muscle adhesion may be facilitated 
by muco-adhesives, which are found in mucus. Mucus is present in the 
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stratified squamous epithelium, but it is produced by goblet cells. Mucus 
saliva is the source of this substance. Most of the mucins in saliva are 
produced by the tiny salivary glands, which produce around 70% of all 
mucins. Because of the sialic acid and sulfurate residues in mucus, the 
mucus network has a negative charge, which plays a function in mucosal 
adhesion. Hard substances and chemicals can cause delicate tissues 
to rupture. An aqueous solution containing 1% organic and inorganic 
compounds. Among the most important salivary metrics is the rate of 
flow, which is affected by three factors: the time of day, the stimulus 
type and the intensity of the stimuli, respectively. 5.5 is the pH of saliva. 
Sodium and carbonic acid levels rise at high flow rates, and the pH rises. 
To hydrate the formulation, saliva is utilized in quantities of 0.5–2 L each 
day. As a result of oral mucosal water content, hydrophilic polymers are 
preferred as vehicles for oral mucosal drug delivery systems [7].
Absorption mechanism through the cheek mucosa [8]
Absorption mechanism through the cheek mucosa: Mucosal absorption 
through the cheeks two main penetration channels for passively delivering 
drugs exist (Fig. 4). Penetrates can use any route, although depending 
on the drug’s physicochemical qualities, one route is preferred over 
another. Due to the water-soluble nature of the intercellular cytoplasm, 
lipid medicines become less soluble. Cell membranes are lipidic, and 
hydrophilic substances have a low partition coefficient, which makes 
them difficult to flow through. The intercellular gaps become the primary 
barrier to lipophilic chemicals’ penetration, whereas the cell membrane 
becomes the primary barrier to water-soluble compounds’ transport. 
These two transport channels can be used in conjunction with each other 
to allow for solute penetration through the oral epithelium. A minimum 
roadblock, on the other hand, dominates the prevailing way [8].
FAST DISOLVING FILMS [9‑11]
A film that dissolves in the mouth is known as Fast Dissolving Film 
(FDF) or oral dispersion. This is a sort of oral medication delivery 
method. Transdermal patch technology was used in the development 
of this. It comprises of a thin film that is instantly moistened with saliva 
and placed on the patient’s tongue, where it is absorbed. There is a lot of 
evaporation in this film. As a result, the medication is quickly released 
for absorption into the oral mucosa [4]. Because the film has a vast 
surface area, it disintegrates quickly when it comes into touch with a 
humid environment.
Definition of FDF
Film that dissolves quickly in your mouth is the most sophisticated solid 
dose form due to its flexibility. In contrast to dissolving tablets, quickly 
dissolving active pharmaceutical ingredients (APIs) require less saliva 
to be effective in the oral cavity. Hydrophilic polymer dissolves fast in the 
tongue or cheek mucosa, delivering the medication to the bloodstream. 
To maximise bioavailability, the rapid drug delivery system uses a very 
low dose that will undergo multiple systemic metabolisms [9]. Features 
of speed films [10].












•	 The	drug	enters	 the	 systemic	 circulation,	 although	 the	 first-pass	
effect is small
•	 Provide	site-specific	delivery	and	local	measures
•	 Large	 surface	 area	 availability	 that	 causes	 rapid	 buzzing	 and	
dissolution in the oral cavity
•	 Dosage	accuracy	compared	to	syrup.
Fast dissolving films disadvantages [12]
•	 The	disadvantage	of	 FDS	 is	 that	 the	 strip	 cannot	 contain	 large	
volumes. The volume should be between 140 mg
Fig. 1: Stages in the development of oral solid dosage forms (Bala 
et al. 2013)
Fig. 3: Structure of the oral mucosa
Fig. 4: Pathways of drug absorption (Rathbone et al. 2003)
Fig. 2: Stages in the development of oral solid dosage forms (Bala 
et al. 2013)
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•	 When	using	filmstrip,	the	thickness	in	forming	the	film	has	technical	
drawbacks such as achieving dose uniformity
•	 Packaging	a	film	requires	special	equipment	and	is	not	easy	to	wrap.








ORAL THIN FILM (OTF) CLASSIFICATION [14] (TABLE 1)
Further classified into these three subtypes.
1. Flash emission
2. Mucoadhesive
3. Mucoadhesive sustained release wafers.
Freeze-drying system [15]
The system is the most popular in the world. Product approvals are 
the highest in the world. Using a mould or blister pack, a suspension 
or medication solution is combined with an excipient. A tablet-shaped 
unit is created. This is followed by lyophilization, which is the freezing 
of purification in packs and moulds. There is a high porosity in the 
resultant unit, which enables rapid dispersion of water or saliva at 
high speed. The active ingredient determines how well these systems 
regulate volume (water-soluble or insoluble drug). A number of taste-
blocking substances can be included in tablets, which dissolve more 
quickly than syringes.
Compressed tablet-based system [16]
Compressed A conventional purification process is used to prepare the 
system. The hardness and crushing degree of the refining technique 
varies depending on the manufacturing method. To improve product 
protection and blister safety, the decomposition performance and 
packaging requirements are reduced to standard high density 
polyethylene bottles and package designs (such as those from CIMA 
Labs). It concludes with action. A water-soluble excipient or carbon-
releasing or effervescent component is used in Bunhe’s formulation 
to allow water to quickly infiltrate the purified core. Biovail Fuisz 
is an exception to this technology for purification. Using the shear 
form system, candy floss containing the medication is created. When 
combined with taste-hidden particles, the technology has the potential 
to integrate enormous quantities of psychoactive compounds. The 
main disadvantage is that it takes longer than thin or lyophilized 
formulations.
TISSUE FILM FOR ORAL USE (OTF) [17]
If you’ve never heard the term oral wafer, it’s a set of flat thin sheets of 
film that’s taken orally. For many years, this type of film system has been 
used in the pharmaceutical industry, but it was just recently discovered 
in a new field. There have been soluble OTF or OS respiratory strips 
on the market for several years in confectionary and oral care items. 
Polymer coating companies with experience in developing APIs for 
transdermal drug.
Delivery is leveraging this OTF technology. Fast-dissolving technology 
classification (Bala et al., 2013) Formalized, OTF is a proven and 
accepted technology that transmits drugs systemically. OTC drugs 
are in the early to mid-term development stage of prescription drugs 
(Table 2).
Composition standard of oral-acting strips dissolving film for oral 
consumption [18]
API is contained in a thin, flat film with a surface area of 120 cm2 
(depending on dose and drug load). There is no limit to how much 
medicine can be put into a single dose. Most of the effects of mechanical 
characteristics of the film are attributed to formulation considerations 
(plasticizer polymer, etc.) (Table 3).
FORMULARITY [19]
Formulation of solvents Water-soluble polymers are dispersed in 
water at a high speed of 1000 rpm and heated to 60°C in this process. 
Colors, flavours, and sweeteners are dissolved in a separate cup. A high-
speed (1000 rpm) mixer was then used to mix the above solutions 
together. In a suitable solvent, the resultant solution is combined with 
the prelocular API. In a vacuum, the bubbles are squandered. It is then 
selected in the film and allowed to dry, after which the film is cut into 
the desired size pieces.
The hot melt extrusion [20,21]
To begin, the operator was used to create a starting volume of material. 
Drugs are mixed with the shrubs and solid volume to create an initial 
volume before being dried. After that, the dried granular material is 
placed in the extruder for further processing. There are four different 
temperatures on an extruder: surface 1 (800°C), surface 2 (1150°C), 
surface 3 (1000°C), and surface 4 (650°C). Extruder screw speed must 
be set to 15 rpm to melt the mass correctly in 34 min. 650°C extrusion 
into cylindrical cylinders forms thin film by pressing the extrusion.
A half-resistance time [22,23]
Spell insoluble polymeric acid is employed in electrical formulae when 
this approach is applied. As a result of this process, dissolved polymers 
are dissolved in local water. This solution was then added to the acidic 
polymer solution to create a new solution. Plasticizers were added after 
a proper mixing of two-soluble solutions to create a gel mass. Finally, 
the gel volume is put into the drum with the temperature protected by 
a thermometer. Then, the two solutions are carefully blended together. 
There must be a tolerance of 0.01510.051 in the width of the produced 
film.
Distributions [24]
Distributions [24] are fixed. In this approach, the medication is 
dispersed in a liquid polymer solution. For solid dispersion, oral 
medicine is dispersed in a solvent and the resulting solution is then 
added to melting the appropriate polymer at temperatures below 70°C 
without removing any liquid solvent. Last but not least, a dye-fixed 
dispersion was transferred to the nitrate-based film.
Methods for rolling [25-27]
How to roll As a result of the rolling approach, both polymer and 
medication solutions are continually combined before being subjected 
Table 1: Types of oral thin films with their properties
Properties Flash release Mucoadhesive melt-away wafers Mucoadhesive sustained released wafers
Area (cm2) 2–8 2–7 2–4
Thickness (µm) 20–70 50–500 50–250
Structure Single layer Single or multilayer Multilayer system
Excipients Soluble hydrophilic polymers Soluble hydrophilic polymers Low/nonsoluble polymers
Drug phase Solid solution Solid solution or suspended drug particle Suspension and/or solid solution
Application Tongue (upper palate) Gingival or buccal region Gingival, (other region in the oral cavity
Dissolution 60 s In few minutes forming gel Maximum 8–10 h
Site of action Systematic or local Systematic or local Systematic or local
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to rollers. There must be a particular viscosity in the solution. There are 
several ways to trim and shape the film when it dries.
Patent-protected approach [28,29]
In this film, you’ll find a wide range of pharmaceuticals and health 
products. As the name implies, it’s a vegetarian dish. With its official 
transformation and nonstop production mechanism removed, the film 
has a more open production environment. Movies In addition to facial 
covering and colouring, Gels TM can be used with pharmaceuticals. 
Different water-soluble polymers, which are carefully optimised for 
application purposes, are used to create this form of film.
Solulaser [30]
Solulaser Oral delivery films containing active ingredients, colors, and 
fragrances are produced using this method. When stored on the tongue, 
the Solulaser TM membrane is engineered to disintegrate fast, releasing 
the active and taste components quickly. As a result of these properties, 
these films are palatable and transport medications quickly to the 
mouth. Soluleave TM tablets or capsules can also be made to adhere 
to the mucous membrane and release active ingredients over a period 
of more than 15 min, making this governance regime ideal for persons 
with patients or elderly age difficulties.
WaFtab [31]
In a well-equipped filmstrip, this is a pharmaceutical distribution 
system. If you’re using WaferTab, the wavy saliva area enables quick 
dissolution and release of active components. WaFtab TM is a film 
strip that can be flavoured to improve flavor masking. In the XGEL TM 
Musiced film, the dose of the active component is precisely fixed and 
protected from heat and moisture, resulting in a more stable dosage. 
Can be produced in a number of forms and sizes, making it ideal for 
patients who have difficulty swallowing medications that require quick 
release.
Oam burst [32]
To create this internal gas flow during the film-making process. When 
the honeycomb structure is broken down, a new emotion is left behind. 
As a result, Foamburst TM has grabbed the attention of confectioners 
and food producer’s alike. Aims to merge specific micro technologies 
and films in 2004 with MICP MICAP SPS. For the notice to cease 
smoking, the development seeks to give novel pharmaceutical supply 
systems for the notification [32].
Asthma [33]
When the airways of the lungs inflame and expand, it becomes difficult 
to breathe and air can’t enter or exit the lungs. For example, people 
with allergies or an ancestry of asthma are more prone to developing 
it. Allergies are often to blame for asthma. An example of this would 
be allergic asthma. There’s a condition called occupational asthma that 
occurs when a worker inhales toxic fumes or gases or powders at work. 
Asthma affects a large number of children and families. Asthma affects 
a large number of children under the age of 5. Exercise-induced asthma 
(EIA): This patient develops asthma due to physical activity. And other 
healthy people suffer from asthma while exercising. This is called EIA.









•	 Some Medicines Example: Aspirin
•	 Respiratory Infections
•	 Temperature Changes and Humidity
•	 Psychological Effects Example: Extreme emotions
•	 Irritation	at	work	Examples:	paint	smoke,	flour,	wood	floor.
Signs and symptoms common signs and symptoms of asthma 
include [35]
•	 Cough - likely to get worse at night
•	 Shortness of breath
•	 Chest stricture
•	 Shortness of breath
•	 Unspeakable (in very severe seizures)
•	 Blue around mouth (in very severe seizures).
ADMINISTRATION
Asthma is not curable, but it can be treated with drugs that are taken 
away from the triggers that cause it to flare. Asthma treatments are 
Table 3: Standard composition of fast dissolving films
Ingredients Amount Examples




45% w/w HPMC E3, E5 and E15 and K-3, 
Methyl cellulose A-3, A-6 and A-15, 
Pullulan, carboxymethylcellulose 
cekol 30, polyvinylpyrrolidone PVP 
K-90, pectin, gelatin, sodium, alginate, 
hdroxypropylcellulose, polyvinyl 
alcohol, maitodextrins
Plastisizers 0–20% w/w Glycerol, dibutyl phthalate, 
polyethylene glycol, etc.,












q.s. FD and C colors, US FDA approved 
flavors
Table 2: Classification of fast dissolving technologies
Properties Lyophilized system Compressed tablet based sysytem Oral thin films
Composition Solution or suspension of drug 
with excipients
Active pharmaceutical ingredient with 
superdisintegrants
Hydrophilic polymers with drug and other 
excipients 
Technology used Lyophilization Direct compression solvent casting, hot melt extrusion
Characteristics High porosity which allow rapid 
water or saliva penetration and 
disintegration
Different levels of hardness and friability these 
results in varying disintegration and packaging 
needs
Large surface area leads to rapid 
disintegration
Packaging Blister Pack High density polyethylene bottles Blister cards with multiunits
Cause [34]
Asthma’s  cause is  still  a  mystery.  Factors  that  contribute to  asthma include: 
Early  childhood  antibiotic  use;  the  number  and  duration  of 
respiratory  infections  during  this  time  period;  genetic 
variables. Occupational exposure to dust and chemicals in most 
asthmatics, the airways are irritated to some degree. In addition, their
 prayers are based on triggers,  or specific  situations.  When an already 
enlarged  prayer  contracts,  it  can  cause  an  asthma  attack.  Asthma 
triggers vary from person to person.
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widely available. Consultants discuss which drugs are best for a certain 
individual patient. Asthma is typically treated with the following types 
of medications: Anti-inducers: Anti-inducers are inhaled corticosteroids 
(ICS) that assist lower stress and diminish the body’s sensitivity to 
inducers in general. Asthma episodes can be prevented by taking it on 
a daily basis. As an example, Flixotide, Pulmicort and Beclozone, resting 
the prayer muscles relieves tension and helps prevent asthma. The term 
bronchodilators are often used to describe them. Taking the palliative 
before a common instigator (exercise) is recommended. Bricanyl 
and Ventolin are two examples. An inhalation palliative given with 
prophylactics. Two doses every day help to keep the prayer muscles 
relaxed. Foradil and Serevent, for example. Combined Inhaler: The 
combined inhaler combines preventative agents and symptomatology 
control into one device. Examples are Seretide and Symbicort. Inflation 
is necessary for the above medications to reach the lungs, where they 
instantly begin to work. Patients with frequent and/or severe asthma 
symptoms may need periodic treatment/therapy adjustments, as 
well as higher medicine dosages. It may be necessary to administer 
corticosteroid medication in liquid or tablet form until the symptoms 
have subsided or disappeared. The symptoms of severe asthma attacks 
must be treated immediately in the hospital. An oxygen nebulizer or 
intravenous infusion is used to treat seizures (injecting into water 
droplets on the hands or arms).
HEALTH‑RELATED ASPECTS [36]
To get approval for a product that is bioequivalent to an existing oral 
medication, the US Food and Drug Administration uses a shorter 
application for new drug approval method. Section 505 (j) of the 
Food, Drug, and Cosmetic Act does not require any clinical studies 
for the approval of generics under this procedure. Here’s an example: 
A bioequivalence study was conducted between an oral disintegrating 
tablet formulation and an oral dissolving film formulation. Develop oral 
film products if you wish. The new clinical study has the advantage of 
giving the product a 3-year commercial exclusivity period. According to 
the European Medicines Agency’s instructions, marketing authorization 
clearance is required in Europe. Either a phase-by-phase approach or 
a mutual approval process is possible. In Japan, product approval is 
handled by the Ministry of Health, Labor, and Welfare. It’s important 
to note that most of the regulation is centerd on taste and palatability, 
especially for products meant for children. These tests are carried out 
on both animals and humans. As for animal research, the hamster ball 
pocket is the most suited model. It’s a trustworthy model that can 
anticipate stimulus requirements before it’s used on humans. Clinical 
endpoints play a crucial role in clinical research. Primary and secondary 
results must be measured. To show the superiority and benefits of the 
newly designed OS over existing formulations. Guidelines for product 
development have been developed by the International Conference 
on Harmonization (ICH). Pharmacists have the option of developing 
drugs in accordance with the Q8 standards from the ICH. The aims 
of clinical research procedures must be well defined. Another aspect 
will be addressed in a separate research study. Study plans must be 
sufficiently detailed (with supporting reasons) to comprehend major 
health risks. For example, soft tissue and/or hard tissue effects are 
taken into account when calculating the size of a study’s sample size. All 
endpoints must be specified. Use patterns (single or many applications) 
are described in this section. Describe the time of follow-up after the 
therapy (for example, a single application with a follow-up period of 
1, 3, 6, or 12 months, multiple applications with a longer follow-up 
period, etc.) As well as a summary of the theme sources, selection 
criteria, and techniques, it should also provide relevant analytical 
information. It is possible that the therapeutic effectiveness and 
bioavailability of the medication will be considerably different from 
traditional formulations due to the distorted elution characteristics. It 
is a non-invasive delivery method that skips the major transit impact 
of altering clinical characteristics. In addition, the safety profile can 
be enhanced by reducing toxic compounds that are formed during 
medication metabolism in the thin mucosa. Faster onset of action leads 
to quicker clinical endpoints. It would be ideal if every strip contained 
exactly enough medication, and the dose form was independent of 
the gastrointestinal tract’s physiological fluctuation, decreasing the 
heterogeneity in clinical response across subjects. While oral mucosal 
medication absorption is quicker than that of traditional medicines, 
which must breakdown and solubilise the active component, there 
is also the risk of an over-release of the drug’s active material during 
the absorption process. A study of its clinical relevance is needed 
to determine its impact. As a result of this rapid response, the safety 
elements of the system must be closely monitored.
COMBINED THERAPY [37‑40]
Combined Therapy for asthma treatment relies on a combination of 
therapies. Xanthenes Category medications and bronchi’s have been 
shown to be effective in several trials. Due to the fact that it improves 
asthma control, and the recommendations recommend it as the 
optimum therapy for individuals with moderate to severe asthma, this is 
the case. Doctors can treat both inflammation and bronchoconstriction 
of asthma using combination treatment, which involves the use of and 
Xanthine in an oral film. Combining Xanthine and Bronchodilator in 
one device is an important step forward in the treatment of asthma, 
given the ability to adjust the dosage of ICS. The complexity of therapy 
must be reduced, especially for patients who require several therapies, 
and patient compliance must be improved. If you’re worried about 
medication penetration into the airways and not treating the systemic 
component of your asthma, mouth dissolving treatment may be able to 
help you with that as well. When used at low therapeutic dosages, the 
inhaled formulation does have a small number of adverse effects for 
both children and adults. Xanthine, according to current research, has 
no major side effects when taken in the therapeutic region. In certain 
research, the safety of Bronchodilator has been called into doubt. 
As a result, regular therapy with this class of drugs isn’t necessary, 
but it should be combined with inhalation since it increases the risk 
of mortality and worsening of severe disease in this patient group of 
people. Steroids even while asthma-related fatalities have not increased 
since the introduction of Xanthenes into clinical practise, according to 
its maker, they have actually decreased. It was also observed that in 
one-third of asthmatics and in half of cases with symptoms increasing, 
inadequate nutrition was to blame.
CONCLUSIONS
When combined with Bronchodilator as a mouth dissolving film, Xanthine 
and Bronchodilator might effectively treat the bronchoconstriction 
component of asthma without the need for additional complimentary 
and synergistic adjustable maintenance dose forms. That’s what I was 
able to do. The use of a film that dissolves in the mouth has been shown 
to be beneficial in treating acute asthma episodes, according to new 
research. In addition, new concepts are used as both a maintenance 
treatment and a relaxation therapy for asthma sufferers since they are 
proven to be safer and more successful than set dosage. Furthermore, 
children as young as 4 years old may now be treated comfortably on 
the combo therapy unit. In addition, the combination device lowers the 
complexity of treatment, allowing for a more personalised approach 
to asthma management. For clinicians, this technique looks perfect, 
as it represents one of the most significant breakthroughs in modern 
asthma therapy. Building collaborative connections between patients 
and healthcare providers cannot be overemphasised. Its goal is to 
empower patients to take charge of their health.
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